The global organoids market was estimated at US$ 59 million in 2023 and is projected to reach about US$ 381.7 million by 2034, expanding at a compound annual growth rate (CAGR) of 18.5% from 2024 to 2034.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5265
Organoids Market: An Overview and Industry Potential
The market is undergoing revolutionary change due to several developments in biomedical research, personalized medicine, and drug discovery. Organoids, which mimic the functions of real organs, are becoming imperative in various fields, such as experimental biology, toxicology, drug discovery, and regenerative medicine. The market is experiencing significant growth due to the rising focus on drug discovery.
Moreover, with the growing prevalence of cancer, investments in cancer research are increasing to develop targeted therapies, contributing to the growth of the market. According to the International Agency for Research on Cancer (IARC), organoid models have recently drawn attention, as cancer is becoming one of the most critical health issues worldwide, and the incidence volume is expected to increase annually by 60% 2040. The National Cancer Institute reported that there were almost 20 million new cases and 9.7 million cancer-related deaths worldwide in 2021.
Major Trends in the Organoids Market
- Increasing Demand for Personalized Treatments: The rising need for personalized treatments is expected to boost the use of organoids in research and clinics. These 3D tissues provide a platform to study the progression of diseases and test drug responses tailored to individual patients. Cancer organoids are currently being used to determine the effectiveness of novel cancer drugs for a given patient, raising the effectiveness of treatments. Furthermore, organoids are becoming essential in drug discovery for rare and genetic diseases.
- New Technologies Emerging in the Culture of Organoids: Ongoing developments in technology and capacities, including CRISPR-Cas9 and 3D bioprints, are revolutionizing the manufacturing and use of organoids. According to National Institute of Health (NIH), CRISPR/Cas9 technology has become the most examined gene editing technology in recent years due to its simple design, low cost, and high efficiency. These innovations allow for mass production of organoids. Gene-editing by CRISPR has enabled the development of genetically engineered organoids that are vital in the study of genetic diseases and gene therapies.
- Support from Government and Nonprofit Organizations: Government entities and nonprofit institutions are funding organoid projects, allowing researchers to innovate and advance organoid technologies. In August 2024, the U.S. National Science Foundation invested USD 14 million in seven interdisciplinary research projects through the Emerging Frontiers in Research and Innovation (EFRI) Biocomputing through EnGINeering Organoid Intelligence program. This investment fosters fundamental and ethically responsible research and development of organoid intelligence systems while also broadening participation in biocomputing research.
Get the latest insights on healthcare industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership
Insights from Key Regions
Well-established R&D Facilities Contributed to North America’s Dominance
North America dominated the market in 2023 and is projected to sustain its dominance in the near future. This is mainly due to the presence of well-established research and development facilities and the rising government funding in research programs. Moreover, the region boasts many biotechnology companies that are focusing on pioneering developments in organoids. As stated by the U.S. National Institutes of Health (NIH), federal funding for organoid research has been steadily rising from the past few years and is expected to change the entire landscape of healthcare.
Furthermore, certain bodies such as the FDA have been instrumental in enhancing how organoid-based therapies are approved. In 2022, the NIH identified a total of 672 patents related to organoid technology. The rising investments in drug discovery and personalized medicine further contribute to regional market growth.
Strong Emphasis on Stem Cell Research to Support Market in Asia Pacific
The organoids market in Asia Pacific is expected to expand at a rapid pace in the coming years due to the increasing focus on stem cell research. The rapid expansion of the biotechnology industry also contributes to market expansion in the region. China and Japan are at the forefront in investing in organoids and stem cell research.
The Stem Cell Institute reports that the Japanese government invests heavily in research of adult stem cells and organoids, revolutionizing regenerative medicine and drug testing. Additionally, the rising cases of cancer and the increasing demand for precision medicines contribute to growth of the market in Asia Pacific.
Organoids Market Segmentation
- On the basis of type, the stem cell source segment led the market in 2023, as stem cell-derived three-dimensional organoid cultures provide new opportunities for regenerative medicine and transplantation. These organoids are critical in mimicking human tissues for therapeutic applications, offering significant potential for the development of personalized treatments. On the other hand, the tumor cell source segment is anticipated to grow rapidly during the forecast period. This is primarily due to its extensive use in drug sensitivity studies and situ malignancy research. Moreover, it plays a key role in cancer drug development.
- Based on application, the pharmaceutical R&D segment accounted for the largest share of the organoids market in 2023. This is mainly due to the increased investments in pharmaceutical R&D. Moreover, the rise in demand for advanced therapeutics and drug testing methods bolstered the segment. On the other hand, the precision medicine segment is anticipated to expand at the fastest rate in the coming years. The segment growth is primarily attributed to the increasing focus on developing precise and reliable in vitro and in vivo disease models, which are essential for advancing personalized medicine approaches.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Competitive Landscape and Major Breakthroughs in the Market
Key players competing in the organoids market include Hub Organoids, Definigen, Cellesce Ltd., Thermo Fisher, Sanofi, NeyroblastGX, StemCell Technologies, Organoid Therapeutics, Bio-Techne, Thermo Fisher Scientific Inc., 3Dnamics Inc., PeproTech Inc., Molecular Devices, LLC, Merck KGaA, Corning Inc., and CN Bio Innovations Ltd. These companies are focusing on bringing innovations to the market.
HUB Organoids B.V. Awarded Frost & Sullivan’s 2024 Technology Innovation Leadership Award for Transforming Drug Development with Highly Advanced Organoid Technology. HUB Organoids is a global leader in patient-derived organoid (PDO) technology that enables drug developers to identify and validate clinical candidates in a patient-relevant in vitro system.
Recent Developments
- In June 2024, Molecular Devices opened a custom-built facility in Cardiff, UK, dedicated to scaling patient-derived organoid (PDO) manufacturing. This multi-million-pound site supports the company’s proprietary bioprocess technology, offering reproducible PDOs in assay-ready format.
- In July 2023, Molecular Devices, LLC expanded its organoid line services, utilizing proprietary bioreactor and bioprocess technology to scale up the production of standardized, assay-ready organoids from customer-supplied or patient-derived xenografts (PDX). This service follows the company’s 2022 acquisition of Cellesce.
- In March 2023, MIMETAS introduced its Adult Stem Cell (ASC)-derived tubular organoids in an assay-ready format. Part of its OrganoReady® product line, these include ASC-derived Colon1 and Kidney2 Organoid tubules, advancing organ-on-a-chip disease modeling.
- In February 2023, TheWell Bioscience introduced the VitroGel® Organoid Recovery Solution, designed to harvest organoids more efficiently. It recovers organoids from both animal-based ECM and synthetic VitroGel hydrogels in just 15 minutes, significantly faster than current market solutions.
Browse More Insights of Towards Healthcare:
The global AI in medical coding market size was projected at USD 2.06 billion in 2022 to reach around USD 7.15 billion by 2032, staggering at a CAGR of 13.3% between 2023 and 2032.
The global life science tools market size was valued at USD 111.28 billion in 2022 to soar around USD 367.16 billion by 2032, expanding at a CAGR of 13% between 2023 and 2032.
The global 5G healthcare market size to grow from USD 41.89 billion in 2022 to reach around USD 266.60 billion by 2032, expanding at a double digit CAGR of 20.82% between 2023 and 2032.
The global metaverse in healthcare market size was valued at USD 8.29 billion in 2022 and is projected to hit USD 81.99 billion by 2032, growing at a CAGR of 26.3% between 2023 and 2032.
The global health insurance market size was estimated at USD 1.54 trillion in 2022 to hit around USD 3.02 trillion by 2032, growing at a CAGR of 7.4% between 2023 and 2032.
The global AI in breast imaging market size to grow from USD 480 million in 2022 to reach around USD 734.24 million by 2032, at a CAGR of 3.30% between 2023 and 2032.
The global bionic eye market size was valued at USD 91.98 million in 2022 to reach around USD 199.97 million by 2032, growing at a CAGR of 8.89% from 2023 to 2032.
The artificial intelligence (AI) in precision medicine market size is projected to grow from USD 1.74 billion in 2022 to reach around USD 16.91 billion by 2032, registered at a CAGR of 25.54% between 2023 and 2032.
The global AI in ultrasound imaging market was valued at USD 881.2 million in 2022 to surpass an estimated USD 2,001.51 million by 2032, expanding at a CAGR of 8.6% between 2023 and 2032.
The global antacids market size is estimated to grow from USD 7.00 billion in 2022 to surpass around USD 9.64 billion by 2032, registered at a CAGR of 3.30% between 2023 and 2032.
Segments Covered in the Report
By Type
- Stem Cell Source
- Tumor Cell Source
By Application
- Pharmaceutical R & D
- Precision Medicine
- Academic & Research Institute
By Region
- North America
- U.S.
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Thailand
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East and Africa (MEA)
- South Africa
- UAE
- Saudi Arabia
- Kuwait
View in-depth TOC of Organoids Market: https://www.towardshealthcare.com/table-of-content/organoids-market-sizing
Acquire our comprehensive analysis today @ https://www.towardshealthcare.com/price/5265
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Gain access to the latest insights and statistics in the healthcare industry by subscribing to our Annual Membership. Stay updated on healthcare industry segmentation with detailed reports, market trends, and expert analysis tailored to your needs. Stay ahead of the curve with valuable resources and strategic recommendations. Join today to unlock a wealth of knowledge and opportunities in the dynamic world of healthcare: Get a Subscription
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.
Browse our Brand-New Journals:
https://www.towardspackaging.com
https://www.towardsautomotive.com
https://www.precedenceresearch.com
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
Get Our Freshly Printed Chronicle: https://www.healthcarewebwire.com
